English, Article edition: Cost Effectiveness of Abciximab During Routine Medical Practice Shelby Ogilvie Reed; C. Daniel Mullins; Laurence S. Magder

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/94180
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost Effectiveness of Abciximab During Routine Medical Practice
Author
  • Shelby Ogilvie Reed
  • C. Daniel Mullins
  • Laurence S. Magder
Physical Description
  • article
Notes
  • Objective: To estimate the cost per ischaemic event (death, nonfatal myocardial infarction, subsequent revascularisation procedure) avoided at 6 months in high risk patients undergoing coronary revascularisation treated with abciximab during routine medical care. Design: Retrospective, matched cohort design. Setting: University teaching hospital. Patients: 62 abciximab-treated patients and 62 patients not treated with abciximab with high risk coronary lesions were matched according to gender, hyperlipidaemia, diabetes mellitus and stenting. Main Outcome Measures: Using a third-party payer's perspective, an incremental cost-effectiveness ratio (ICER) was computed as the cost per ischaemic event avoided over 6 months. Fieller's theorem was used to estimate confidence sets and confidence ellipses were generated to visually represent the variability in the data. Results: At 6 months, abciximab-treated patients experienced an approximately 40% lower rate of ischaemic events (16.1 vs 27.4%; p =​ 0.128). The point estimate of the ICER was $US21 789 per ischaemic event avoided. Fieller's theorem resulted in a 95% confidence set consisting of 2 half-lines (-infinity to -$US115 461) and ($US391 to +infinity), reflecting the finding that the ICER denominator was not significantly different from zero at the p =​ 0.05 level. Conclusions: In high risk patients treated during routine care, the effectiveness of abciximab was consistent with efficacy rates from clinical trials. However, abciximab-treated patients remained approximately $US2400 more costly at 6 months.
  • Abciximab, Antithrombotics, Coronary disorders, Cost effectiveness, GPIIb IIIa antagonists, Pharmacoeconomics
  • RePEc:wkh:phecon:v:18:y:2000:i:3:p:265-274
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment